olmesartan has been researched along with risedronic acid in 2 studies
| Studies (olmesartan) | Trials (olmesartan) | Recent Studies (post-2010) (olmesartan) | Studies (risedronic acid) | Trials (risedronic acid) | Recent Studies (post-2010) (risedronic acid) |
|---|---|---|---|---|---|
| 841 | 185 | 554 | 1,318 | 290 | 487 |
| Protein | Taxonomy | olmesartan (IC50) | risedronic acid (IC50) |
|---|---|---|---|
| Farnesyl pyrophosphate synthase | Homo sapiens (human) | 0.1104 | |
| Farnesyl pyrophosphate synthase | Leishmania donovani | 0.1699 | |
| Farnesyl diphosphate synthase | Toxoplasma gondii | 0.074 | |
| Farnesyl diphosphate synthase | Trypanosoma cruzi | 0.027 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Biecek, P; Kaza, M; Rudzki, PJ | 1 |
2 other study(ies) available for olmesartan and risedronic acid
| Article | Year |
|---|---|
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Extended 3D and 4D cumulative plots for evaluation of unmatched incurred sample reanalysis.
Topics: Analysis of Variance; Antihypertensive Agents; Antineoplastic Agents; Bone Density Conservation Agents; Computer Graphics; Datasets as Topic; Humans; Imatinib Mesylate; Imidazoles; Reproducibility of Results; Risedronic Acid; Tetrazoles | 2018 |